Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2015

View Archived Issues

Purdue Pharma divulges new opioid receptor agonists

FDA advisory committee completes new review of Fabre-Kramer's gepirone ER

S1P2 receptor antagonist shows promise for fibrosis

Probing the role of FKBP5 in the epigenetic effects of paroxetine

Phase III trial AFFINITY of custirsen in mCRPC to continue following futility analysis

FAK inhibitor GSK-2256098 reaches glioblastoma tumor tissue in patients

Ignyta's entrectinib first drug selected for the SPECTA biomarker screening initiative

Bristol-Myers Squibb discloses HCV NS5B inhibitors

Roche and Genentech present JAK inhibitors

Newron begins U.S. phase II trial of NW-3509 in patients with schizophrenia

Kamada provides update on alpha1-antitrypsin development in type 1 diabetes

Shionogi's Mulpleta launched in Japan

Reinnervate's Alvetex scaffold used in 3D models of skin and neuronal tissue

Atea plans clinical development of new hepatitis C virus polymerase inhibitors

Anti-survivin vaccine induces immune response in phase II trial in DLBCL

GSK launches Nucala in U.S.

Assurex Health expands utility of GeneSight Psychotropic test

Phase I trial results of T1D immunotherapy with autologous polyclonal Tregs

ORIC Pharmaceuticals announces Series B financing

Apricus confirms strategy for fispemifene, following FDA guidance on enclomiphene

Pradigastat reduces liver fat in patients with nonalcoholic fatty liver disease

HiberGene's meningococcal disease diagnostic receives CE Mark

TxCell reacquires full rights to Ovasave

Celleron reports results from first clinical study of HDAC inhibitor CXD-101

FDA places Zafgen's phase III trial of beloranib in Prader-Willi syndrome on full clinical hold

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...